With more than 10,000 employees worldwide, this global pharmaceutical company takes a patient-first approach to therapeutic development, focusing on neurology and oncology. In addition to running clinical trials and producing four global brands, its researchers are exploring how to measure biomarkers for Alzheimer’s treatments and leverage DNA sequences to fight cancer more effectively.
However, the company’s ability to perform pharmaceutical research and development, and deliver the best service possible to its customers was inhibited by three primary issues: an outdated data storage solution, inaccessible and siloed data, and enterprise-wide reliance on sensitive data use.
To improve patient outcomes, scale cost efficiencies, and fuel drug development and innovation, this global pharmaceutical company needed to balance sensitive data sharing with strict regulatory requirements. See how they leveraged Immuta to:
- Break down data silos and eliminate the need for data copies, which complicated compliance efforts
- Operationalize a BI and analytics platform that enables fast, secure, self-service data access
- Reduce data storage and management costs while increasing efficiency and collaboration
